Free tool
Oncology stocks
We cover 166 companies grouped under the Oncology theme. The median market value in the group is $168.78M. Across the group, the median move over the past trading day is +1.54%. 48% of the 161 with a 200-day average trade above it. Price change over the past year runs from −77.1% to +197.5% across the middle 80 percent of the group, with a median of +5.6%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
166 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | $263.12B | Mega cap | +7.60% |
| A1ZN34.SA | AstraZeneca PLC | $260.90B | Mega cap | +1.51% |
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
| IMCR | Immunocore Holdings plc | $1.93B | Small cap | +14.76% |
| DMRA | Damora Therapeutics, Inc. | $1.89B | Small cap | +800.59% |
| VIR | Vir Biotechnology, Inc. | $1.81B | Small cap | +144.52% |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.77B | Small cap | +27.20% |
| BCAX | Bicara Therapeutics Inc. | $1.63B | Small cap | +117.14% |
| AAPG | Ascentage Pharma Group Internat | $1.57B | Small cap | −61.38% |
| AVBP | ArriVent BioPharma, Inc. | $1.55B | Small cap | +62.02% |
| REPL | Replimune Group, Inc. | $1.49B | Small cap | +187.80% |
| AKTS | Aktis Oncology, Inc. | $1.48B | Small cap | +19.15% |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.40B | Small cap | +43.76% |
| DRTS | Alpha Tau Medical Ltd. | $1.36B | Small cap | +357.94% |
| IMTX | Immatics N.V. | $1.26B | Small cap | +76.67% |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.24B | Small cap | +217.21% |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.22B | Small cap | +167.16% |
| CADL | Candel Therapeutics, Inc. | $1.04B | Small cap | +138.18% |
| GERN | Geron Corporation | $995.83M | Small cap | +9.15% |
| OLMA | Olema Pharmaceuticals, Inc. | $954.60M | Small cap | +95.17% |
| ANL | Adlai Nortye Ltd. | $884.83M | Small cap | +737.80% |
| RIGL | Rigel Pharmaceuticals, Inc. | $864.97M | Small cap | +14.75% |
| AURA | Aura Biosciences, Inc. | $810.97M | Small cap | +19.94% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $751.23M | Small cap | −3.50% |
| MNPR | Monopar Therapeutics Inc. | $747.47M | Small cap | +264.30% |
| CTMX | CytomX Therapeutics, Inc. | $734.32M | Small cap | +68.50% |
| GUD.TO | Knight Therapeutics Inc. | $692.32M | Small cap | +49.08% |
| EIKN | Eikon Therapeutics, Inc. | $679.77M | Small cap | −16.33% |
| VSTM | Verastem, Inc. | $641.19M | Small cap | −21.16% |
| SGMT | Sagimet Biosciences Inc. | $639.61M | Small cap | +45.34% |
| CBIO | Crescent Biopharma, Inc. | $630.33M | Small cap | +15.65% |
| ARVN | Arvinas, Inc. | $610.71M | Small cap | +28.34% |
| DCTH | Delcath Systems, Inc. | $587.10M | Small cap | +55.37% |
| CCCC | C4 Therapeutics, Inc. | $516.71M | Small cap | +66.01% |
| TOI | Starling Oncology Inc | $512.91M | Small cap | +78.67% |
| RLMD | Relmada Therapeutics, Inc. | $489.61M | Small cap | +635.58% |
| PBYI | Puma Biotechnology, Inc. | $470.77M | Small cap | +86.77% |
| CMPX | Compass Therapeutics, Inc. | $455.62M | Small cap | −16.23% |
| FENC | Fennec Pharmaceuticals Inc. | $410.64M | Small cap | +35.38% |
| FHTX | Foghorn Therapeutics Inc. | $406.79M | Small cap | +30.48% |
| GALT | Galectin Therapeutics Inc. | $402.39M | Small cap | −0.25% |
| FRX.TO | Fennec Pharmaceuticals Inc. | $392.65M | Small cap | +27.38% |
| AGEN | Agenus Inc. | $376.28M | Small cap | +90.43% |
| CATX | Perspective Therapeutics, Inc. | $375.56M | Small cap | −4.91% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $367.33M | Small cap | +113.19% |
| STRO | Sutro Biopharma, Inc. | $355.50M | Small cap | +155.24% |
| IMRX | Immuneering Corporation | $338.37M | Small cap | −12.10% |
| BCYC | Bicycle Therapeutics plc | $306.47M | Small cap | −38.34% |
| WHWK | Whitehawk Therapeutics, Inc. | $278.20M | Small cap | +198.82% |
| ALXO | ALX Oncology Holdings Inc. | $276.55M | Small cap | +81.82% |
| MGNX | MacroGenics, Inc. Common Stock | $265.63M | Small cap | +154.27% |
| GLSI | Greenwich LifeSciences, Inc. | $258.04M | Small cap | +56.35% |
| PYXS | Pyxis Oncology, Inc. | $255.23M | Small cap | +120.14% |
| IPHA | Innate Pharma S.A. | $253.56M | Small cap | +1.34% |
| ADAG | Adagene Inc. | $252.40M | Small cap | +62.55% |
| TARA | Protara Therapeutics, Inc. | $234.61M | Small cap | +30.16% |
| NBP | NovaBridge Biosciences | $218.58M | Small cap | −59.96% |
| CHRS | Coherus Oncology, Inc. | $211.67M | Small cap | +17.09% |
| MENS | Jyong Biotech Ltd. | $168.78M | Small cap | −95.26% |
| CUE | Cue Biopharma, Inc. | $168.39M | Small cap | +9.05% |
| MOLN | Molecular Partners AG | $164.30M | Small cap | +3.91% |
| KZIA | Kazia Therapeutics Limited | $157.58M | Small cap | +83.87% |
| OKUR | OnKure Therapeutics, Inc. | $155.52M | Small cap | +36.77% |
| INDP | Indaptus Therapeutics, Inc. | $145.90M | Small cap | −84.51% |
| ADCT | ADC Therapeutics SA | $132.77M | Small cap | −66.34% |
| HURA | TuHURA Biosciences, Inc. | $130.00M | Small cap | −30.85% |
| LIXT | Nomad Power Solutions Inc | $125.36M | Small cap | +26.14% |
| BDTX | Black Diamond Therapeutics, Inc. | $123.81M | Small cap | −21.95% |
| ANIX | Anixa Biosciences, Inc. | $123.16M | Small cap | +22.00% |
| GNLX | Genelux Corporation | $123.07M | Small cap | −27.27% |
| NTHI | NeOnc Technologies Holdings, Inc. | $122.16M | Small cap | −18.72% |
| ONCY | Oncolytics Biotech Inc. | $109.84M | Small cap | −12.99% |
| AMAN | Amanat Acquisition Corp | $103.43M | Small cap | +6.79% |
| JATT | JATT II Acquisition Corp. | $97.15M | Micro cap | +18.62% |
| ACRV | Acrivon Therapeutics, Inc. | $93.42M | Micro cap | +63.91% |
| MAIA | MAIA Biotechnology, Inc. | $85.78M | Micro cap | −10.76% |
| CTOR | Citius Oncology, Inc. | $85.68M | Micro cap | −57.14% |
| VRCA | Verrica Pharmaceuticals Inc. | $83.66M | Micro cap | −17.53% |
| CRDF | Cardiff Oncology, Inc. | $79.35M | Micro cap | −53.85% |
| ELTX | Elicio Therapeutics, Inc. | $79.11M | Micro cap | −72.71% |
| OSTX | OS Therapies Incorporated | $76.68M | Micro cap | −24.66% |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −23.49% |
| XBIT | XBiotech Inc. | $70.43M | Micro cap | −28.13% |
| PMVP | PMV Pharmaceuticals, Inc. | $69.76M | Micro cap | −8.10% |
| BOLD | Boundless Bio, Inc. | $67.33M | Micro cap | +160.18% |
| RNXT | RenovoRx, Inc. | $64.08M | Micro cap | +58.13% |
| HRTX | Heron Therapeutics, Inc. | $61.34M | Micro cap | −76.59% |
| XLO | Xilio Therapeutics, Inc. | $59.75M | Micro cap | −7.35% |
| IMMP | Immutep Limited | $56.28M | Micro cap | −77.54% |
| TIL | Instil Bio, Inc. | $51.54M | Micro cap | −69.62% |
| IBO | Impact BioMedical Inc. | $49.62M | Micro cap | −20.79% |
| BKHA | Black Hawk Acquisition Corporation | $49.39M | Micro cap | +8.09% |
| CNTX | Context Therapeutics Inc. | $40.00M | Micro cap | −50.13% |
| ATNM | Actinium Pharmaceuticals, Inc. | $33.88M | Micro cap | −39.66% |
| BCTX | BriaCell Therapeutics Corp. | $32.80M | Micro cap | −49.67% |
| BCT.TO | BriaCell Therapeutics Corp. | $32.32M | Micro cap | −50.62% |
| BYSI | BeyondSpring Inc. | $29.61M | Micro cap | −60.43% |
| MDNA.TO | Medicenna Therapeutics Corp. | $29.00M | Micro cap | −58.77% |
| EVAX | Evaxion A/S | $28.36M | Micro cap | +4.49% |
| LTRN | Lantern Pharma Inc. | $27.87M | Micro cap | −52.30% |
| NXTC | NextCure, Inc. | $27.05M | Micro cap | +13.33% |
| PSTV | Plus Therapeutics Inc | $26.64M | Micro cap | −68.67% |
| ATOS | Atossa Therapeutics, Inc. | $26.35M | Micro cap | −76.49% |
| CVM | CEL-SCI Corporation | $26.03M | Micro cap | −85.98% |
| MRKR | Marker Therapeutics, Inc. | $25.34M | Micro cap | +20.63% |
| CLRB | Cellectar Biosciences, Inc. | $24.01M | Micro cap | −45.96% |
| CCM | Concord Medical Services Holdings Limited | $21.49M | Micro cap | −10.65% |
| ABVC | ABVC BioPharma, Inc. | $21.32M | Micro cap | −72.70% |
| ALLR | Allarity Therapeutics, Inc. | $21.16M | Micro cap | +41.34% |
| TPST | Tempest Therapeutics, Inc. | $18.36M | Micro cap | −89.50% |
| CTXR | Citius Pharmaceuticals, Inc. | $16.57M | Micro cap | −52.09% |
| MDCX | Medicus Pharma Ltd. | $16.26M | Micro cap | −87.97% |
| INTS | Intensity Therapeutics, Inc. | $15.98M | Micro cap | −37.24% |
| LSTA | Lisata Therapeutics, Inc. | $15.68M | Micro cap | −31.23% |
| AKTX | Akari Therapeutics, Plc | $14.54M | Micro cap | −77.77% |
| PHIO | Phio Pharmaceuticals Corp. | $13.82M | Micro cap | −41.21% |
| GTBP | GT Biopharma, Inc. | $13.52M | Micro cap | −72.50% |
| BLRX | BioLineRx Ltd. | $12.45M | Micro cap | −25.97% |
| TOVX | Theriva Biologics, Inc. | $10.90M | Micro cap | −45.33% |
| LNAI | Lunai Bioworks Inc. | $9.97M | Micro cap | −87.99% |
| IMNN | Imunon, Inc. | $8.92M | Micro cap | −73.86% |
| CNSP | CNS Pharmaceuticals, Inc. | $8.48M | Micro cap | −11.31% |
| AIM | AIM ImmunoTech Inc. | $7.73M | Micro cap | −89.97% |
| BOLT | Bolt Biotherapeutics, Inc. | $7.42M | Micro cap | −29.28% |
| CANF | Can-Fite BioPharma Ltd. | $7.11M | Micro cap | −74.46% |
| ITOC | iTonic Holdings Ltd. | $6.75M | Micro cap | −51.75% |
| LIMN | Liminatus Pharma, Inc. | $6.19M | Micro cap | +35.59% |
| NCNA | NuCana plc | $6.12M | Micro cap | −56.76% |
| PCSA | Processa Pharmaceuticals, Inc. | $6.09M | Micro cap | −60.36% |
| KAPA | Kairos Pharma, Ltd. | $5.88M | Micro cap | −79.82% |
| BCAB | BioAtla, Inc. | $5.43M | Micro cap | −81.69% |
| HCWB | HCW Biologics Inc. | $4.77M | Micro cap | −53.15% |
| APS.TO | Aptose Biosciences Inc | $4.42M | Micro cap | +37.14% |
| OSRH | OSR Health, Inc. | $4.09M | Micro cap | −88.47% |
| RDHL | RedHill Biopharma Ltd. | $3.68M | Micro cap | −55.83% |
| CLDI | Calidi Biotherapeutics, Inc. | $3.39M | Micro cap | −16.03% |
| GOVX | GeoVax Labs, Inc. | $3.34M | Micro cap | −96.61% |
| ARTL | Artelo Biosciences, Inc. | $3.30M | Micro cap | −97.47% |
| NXTS | Nexentis Technologies Inc. | $2.69M | Micro cap | −96.64% |
| PPBT | Purple Biotech Ltd | $2.68M | Micro cap | −92.53% |
| PPCB | Propanc Biopharma, Inc. | $2.57M | Micro cap | −98.66% |
| TRAW | Traws Pharma, Inc. | — | — | −58.95% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.